Defence Therapeutics to Present at the Life Sciences Virtual Investor Forum December 11th

Defence Therapeutics, a biotechnology company located at adMare BioInnovations Technoparc in Montreal, is poised to present at the Life Sciences Virtual Investor Forum on December 11, 2025. The company, which operates under the ticker symbol OTCQB: DTCFF, focuses on revolutionizing antibody-based and radiotherapeutic treatments through its proprietary intracellular delivery platform, known as ACCUM®. This innovative technology allows for the precise delivery of biologics in their intact form, enhancing their potency and safety, thus creating more effective treatment options.

Amie Phinney, PhD, MBA, the Director of Strategy & Business at Defence Therapeutics, will be leading the presentation. The event starts at 11:00 a.m. ET, and registered attendees will have the chance to engage in real-time Q&A sessions. For those unable to attend live, an archived webcast of the presentation will be made accessible after the event. Investors interested in private one-on-one meetings with the company can also schedule these for the afternoon of December 11 and on December 15 and 16.

Recent highlights from Defence Therapeutics include positive in vivo efficacy results from their Accum-Kadcyla evaluations in breast cancer models, the expansion of lab capacities, and the establishment of a robust Scientific Advisory Board—a testament to the company’s growth and commitment to advancing medical science.

The Virtual Investor Conferences platform enables companies to present directly to a global audience of retail and institutional investors, creating a seamless interaction that mimics traditional in-person conferences. This provides a valuable opportunity for Defence Therapeutics to connect with potential investors and stakeholders in the life sciences sector.

Defence Therapeutics (OTCQB: DTCFF) is positioning itself as a crucial player in the biotechnology sector, particularly with its advanced intracellular delivery platform. As the company prepares for its presentation at the Life Sciences Virtual Investor Forum on December 11, 2025, it’s essential for investors to grasp the potential implications of both the event and the company's recent developments.

The company has made strides in validating its ACCUM® technology, which enhances the efficacy of biologics, thereby expanding market access and patient treatment opportunities. Positive in vivo efficacy results, particularly concerning the Accum-Kadcyla in breast cancer models, is a significant indicator of the company’s potential to deliver value to stakeholders. This progress is not only critical in terms of clinical outcomes but also strengthens Defence Therapeutics' position in discussions with potential investors.

The opportunity for real-time engagement during the virtual conference could catalyze investor interest. The format allows for interactive participation, where potential investors can ask questions about the company's future direction, strategic partnerships, and plans to expand its laboratory capacities and scientific advisory team. Given that strategic execution is a vital aspect of biotechnology firms, the insights shared during these 1x1 meetings could drive interest and provide clarity on the company's trajectory.

Investors should monitor the outcome of this forum closely. A successful presentation could boost investor confidence and lead to increased share volume, as it provides a platform for Defence Therapeutics to discuss their growth narrative. The stock may see a positive reaction, particularly if the company can effectively communicate its advancements and reinforce its strategy for scalable growth. Therefore, for potential investors, attending the presentation or accessing the archived material could provide valuable insights into the future appraisal of Defence Therapeutics’ stock.